Cellectis

Calyxt increased the number of shares it intends to float, but slashed its offering price in half from the middle of a previously disclosed range.

The technology is for gene targeting using endocunleases and homologous recombination, and is the second licensing deal between the parties since April.

The firm adds CRISPR/Cas9 gene editing to its portfolio of plant genome engineering technologies, which also includes meganucleases and TALENs.

Based in New York, the subsidiary will feature laboratory space to develop the firm's chimeric antigen receptor T cells for cancer immunotherapy.

The gene editing company priced its initial public offering of 5.5 million American Depositary Shares with expectations of going public on the Nasdaq. 

The arrangement covers Cellectis' TALEN technology and Two Blades' TAL effector code technology.